Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Last trade$4.66
Day change-$0.17 (-3.52%)
Day range$4.55 – $5.02
Volume767,202
Market cap$546M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$546.3M
Price / earnings
—
Price / book
1.47×
Price / sales
0.23×
EV / sales
0.58×
EV / EBITDA
21.71×
Profitability
Earnings per share
-$4.49
Return on assets
-25.87%
Return on equity
-136.17%
Dividend yield
0%
Liquidity and leverage
Debt / equity
2.6×
Current ratio
1.26×
Quick ratio
1.26×
Cash ratio
0.3×
Cash flow
Price / cash flow
8.42×
Price / free cash flow
9.56×
Free cash flow
$57.12M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EVH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$725.37M
$652.52M
$496.25M
$468.72M
$479.53M
$444.33M
$483.65M
$646.54M
Cost of revenue
$636.95M
$571.68M
$412.47M
$371.47M
$379.76M
$343.94M
$381.18M
$570.83M
Gross profit
$88.42M
$80.84M
$83.77M
$97.25M
$99.77M
$100.39M
$102.47M
$75.71M
Selling, general and administrative
$73.12M
$68.83M
$72.82M
$72.66M
$77.59M
$75.21M
$78.41M
$47.7M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$94.61M
$90.4M
$94.37M
$520.35M
$100.12M
$101.56M
$102.47M
$94.31M
Operating income
-$6.19M
-$9.56M
-$10.6M
-$423.1M
-$344K
-$1.17M
$4K
-$18.6M
Interest expense
-$17M
-$16.86M
-$16.87M
-$19.01M
-$16.48M
-$11.6M
-$10.39M
-$6.72M
Income before taxes
-$22.45M
-$25.65M
-$25.72M
-$430.81M
-$19.96M
-$20.72M
-$63.15M
-$23.92M
Income taxes
$1.12M
$2.72M
$910K
-$1.68M
$906K
-$825K
$1.47M
-$1.12M
Net income
-$23.57M
-$28.36M
-$26.63M
-$429.13M
-$20.86M
-$19.9M
-$64.62M
-$22.8M
Net income attributable to common shareholders
-$23.57M
-$28.36M
-$26.63M
-$429.13M
-$26.93M
-$51.09M
-$72.25M
-$30.62M
EBITDA
$16.32M
$13.1M
$11.89M
$21.71M
$26.45M
$23.26M
$25.3M
$33.4M
Basic earnings per share
-$0.21
-$0.25
-$0.24
-$3.85
-$0.24
-$0.44
-$0.63
-$0.27
Diluted earnings per share
-$0.21
-$0.25
-$0.24
-$3.85
-$0.24
-$0.44
-$0.63
-$0.27
Recent news
Company coverage with links to the original publishers.
American Well (AMWL) shares jumped 6.1% to $14.98 on investor optimism ahead of Q3 2026 earnings expected November 3. The company is projected to report a quarterly loss of $0.66 per share (62.1% improvement year-over-year) with revenues of $47.06 million (down 16.4%). However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to sustain momentum without positive estimate trends. AMWL carries a Zacks Rank #3 (Hold).
The value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.
The Dr. Abeer AbouYabis Scholarship for Future Doctors offers a $1,000 award to undergraduate students pursuing a medical career, encouraging them to envision their impact on the future of healthcare.
The global technology spending on core administration in healthcare market is expected to grow from $34.8 billion in 2023 to $61.5 billion by 2033, at a CAGR of 5.86%. The growth is driven by advancements in technologies like edge computing, IoT, and cloud storage, as well as the need for operational efficiency and regulatory compliance.
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.